() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Tag Archives: Asterion Cannabis Inc

Asterion Retains First Penny Investments to Provide Equity Funding

June 3, 2020 Vancouver, British Columbia:  Asterion Cannabis Inc. (“Asterion” or the “Company”), announces a brokered private placement of up to 6,666,667 units (each, a “Unit”) at the price of CAD $1.50 per Unit, for aggregate gross proceeds of up to CAD $10,000,000 (the “Financing”).  Each Unit will consist of one common share in the capital of the Company (each, a “Share”) and one half a common share purchase warrant (each, a “Warrant”), with each Warrant entitling the holder thereof to purchase one additional Share at a price of CAD$2.00 per Share for a period of 24 months from the closing of the Financing, subject to acceleration.
Read more

Asterion to Participate in the 32nd Annual ROTH Conference

Asterion Cannabis Inc. (“Asterion” or the “Company”), is pleased to announce that it will participate in the 32nd Annual ROTH Conference taking place in Orange County, California, USA, from March 15th – 17th, 2020. Asterion’s Chairman and CEO Stephen Van Deventer will be presenting, as a private company, on March 16th. Stephen will also be conducting one-on-one meetings with investors at the conference.
Read more

PreveCeutical Grants Asterion Option to Purchase up to a 51% Interest in Sol-Gel Intellectual Property

August 6, 2019 PreveCeutical Medical Inc. (“PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), and Asterion Cannabis Inc. (“Asterion”) announce that they have entered into an option to purchase agreement (the “Option Agreement”), whereby PreveCeutical has granted to Asterion the right and option (the“Option”) to purchase up to 51% of PreveCeutical’s right, title and interest in and to certain intellectual property rights relating to a soluble gel (“Sol-Gel”) nasal delivery system for the nose-to-brain delivery of therapeutic formulations, including cannabis and cannabinoids (the “Sol-Gel IP”).
Read more